|Bid||2.4000 x 800|
|Ask||2.6200 x 1100|
|Day's Range||2.3350 - 2.6986|
|52 Week Range||1.3500 - 4.4000|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.83|
Subscribe to Yahoo Finance Plus to view Fair Value for AXLA
CAMBRIDGE, Mass., August 12, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.